TY  - GEN
AU  - Rincón,Raúl
AU  - Cristóbal,Ion
AU  - Zazo,Sandra
AU  - Arpí,Oriol
AU  - Menéndez,Silvia
AU  - Manso,Rebeca
AU  - Lluch,Ana
AU  - Eroles,Pilar
AU  - Rovira,Ana
AU  - Albanell,Joan
AU  - García-Foncillas,Jesús
AU  - Madoz-Gúrpide,Juan
AU  - Rojo,Federico
TI  - PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
SN  - 1949-2553
PY  - 2015///1214
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Animals
KW  - Antibiotics, Antineoplastic
KW  - pharmacology
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Blotting, Western
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Doxorubicin
KW  - Drug Resistance, Neoplasm
KW  - physiology
KW  - Enzyme Activation
KW  - Female
KW  - Humans
KW  - Immunohistochemistry
KW  - Kaplan-Meier Estimate
KW  - Mice
KW  - Mice, Inbred BALB C
KW  - Middle Aged
KW  - Prognosis
KW  - Protein Phosphatase 2
KW  - metabolism
KW  - Real-Time Polymerase Chain Reaction
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.18632/oncotarget.3012
ER  -